secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-138936
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva appoints Matthew Shields as EVP Global Operations; Eric Drapé departs after 11 years
--------------------------------------------------------------------------------

- Matthew Shields becomes EVP Global Operations effective June 3, 2024, based in Parsippany, NJ.
- Shields previously SVP Manufacturing at Merck Animal Health; prior roles at Sanofi and Amgen.
- Initial base salary of $825,000 with 100% target annual cash incentive, equity awards, and $200,000 sign-on cash.
- Eric Drapé leaves Teva after 11 years, including over 4 years as EVP Global Operations.
- Shields reports directly to CEO Richard Francis as part of the Pivot to Growth strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312524138936/0001193125-24-138936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312524138936/d820660d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer